Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd (KIMS Hospitals) has received in-principle approval from BSE and NSE for the preferential issue and allotment of 77,02,182 warrants, convertible into equity shares, to its promoters and promoter group. The issue price for conversion is not less than ₹779 per share. The exchanges have advised the company to strengthen internal controls and obtain undertakings from allottees regarding trading restrictions to ensure compliance with SEBI regulations. KIMS Hospitals must also comply with post-allotment listing formalities within twenty days.

Krishna Institute of Medical Sciences Ltd (KIMS Hospitals) has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, along with a Reasonable Assurance Report from M/s. Brahmayya & Co. The report, which is part of the Integrated Annual Report, details the company's performance against the National Guidelines on Responsible Business Conduct (NGRBC) and SEBI's BRSR framework. It highlights KIMS's approach to ethical governance, sustainability in service delivery, employee well-being, stakeholder inclusiveness, human rights, environmental responsibility, and public policy advocacy. The BRSR emphasizes the integration of sustainability across operations to enhance resilience, improve healthcare outcomes, and create long-term value for all stakeholders.

Krishna Institute of Medical Sciences Ltd (KIMS Hospitals) has submitted its 24th Integrated Annual Report for the Financial Year 2025-26. The report, sent electronically to members, details the company's expansion, operational highlights, and financial performance. KIMS Hospitals operates a network of 26 branches across five states, emphasizing clinical excellence and patient-centric care. The report includes financial statements, statutory reports, and management discussions, highlighting a revenue of ₹39,308 Mn and an EBITDA margin of 21.1% for FY26. The company's vision is to maximize reach and become the most preferred healthcare brand through affordable care and best clinical outcomes.

Krishna Institute of Medical Sciences Ltd has announced its 24th Annual General Meeting (AGM) will be held on August 27, 2026, at 4:00 PM IST. The meeting will be conducted virtually via Video Conferencing/Other Audio Visual Means (VC/OAVM). Key agenda items include the adoption of audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026, the re-appointment of Ms. Dandamudi Anitha as a Director, ratification of remuneration for Cost Auditors M/s. Sagar & Associates for FY 2026-27, and approval for granting loans, guarantees, or securities up to ₹650 Cr to group entities under Section 185 of the Companies Act, 2013.

Krishna Institute of Medical Sciences Ltd (KIMS Hospitals) has dispatched a letter to shareholders regarding its Annual Report for FY 2025-26. This communication, in line with SEBI Listing Regulations, provides a web-link to the Annual Report for members whose email addresses are not registered. The company also announced its 24th Annual General Meeting (AGM) scheduled for August 27, 2026, to be held via Video Conferencing. The notice also serves as a reminder for shareholders holding physical securities to update their KYC details as per SEBI's master circular, including PAN, address, mobile number, bank details, and specimen signature, to ensure eligibility for payments like dividends.

Krishna Institute of Medical Sciences Ltd (KIMS) has reported no deviation in the utilization of funds raised through Qualified Institutional Placement (QIP) for the quarter ended June 30, 2026. The funds, raised via a Placement Document dated June 19, 2026, amounting to ₹1500 Cr, were utilized as per the stated objects. The utilization included ₹910 Cr for repayment of borrowings, ₹215 Cr for investment in subsidiaries for debt repayment, ₹351.45 Cr for general corporate purposes, and ₹23.55 Cr for issue expenses. The Audit Committee reviewed the statement and confirmed NIL deviation or variation. The total funds utilized during the quarter were ₹1086.49 Cr.

Krishna Institute of Medical Sciences Ltd (KIMS) has submitted its Monitoring Agency Report for the quarter ended June 30, 2026. The report, issued by CARE Ratings Limited and reviewed by the company's Audit Committee, pertains to funds raised through a Qualified Institutional Placement (QIP) of ₹1,500 crore. The filing confirms there were no deviations from the objects for which the funds were raised. This report is in compliance with SEBI regulations regarding the utilization of issue proceeds.

Krishna Institute of Medical Sciences Ltd (KIMS Hospitals) announced its unaudited financial results for the first quarter ended June 30, 2026. The company reported a consolidated total revenue of INR 1,196 Cr, marking a significant year-on-year (YoY) growth of 36.1% and a quarter-on-quarter (QoQ) increase of 10.3%. EBITDA stood at INR 240 Cr, up 20.1% YoY and 10.9% QoQ. However, Profit After Tax (PAT) saw a decline to INR 37 Cr from INR 85 Cr in Q1 FY26, leading to a 47.2% YoY degrowth in consolidated EPS to INR 1.04. The company also highlighted operational achievements, including 10,000 brain tumour surgeries at its Secunderabad facility and a complex life-saving surgery for an infant at KIMS Kondapur.

Krishna Institute of Medical Sciences Ltd's Board of Directors has approved the unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. The board also approved advancing loans up to ₹650 Crores to group entities, subject to shareholder approval, and a loan of up to ₹25 crore to its material subsidiary, KIMS Hospital Enterprises Private Limited. Additionally, draft O&M and Call Option agreements with Golden Lan Solutions Private Limited and Sarwottam Healthcare Private Limited were approved.

Krishna Institute of Medical Sciences (KIMS) posted consolidated Q1 FY27 (quarter ended 30 June 2026) revenue of ₹1,179.5 Cr, up 35.3% YoY (₹871.6 Cr) and 9.8% QoQ (₹1,074.6 Cr), but consolidated PAT of ₹37.4 Cr fell 56.0% YoY (₹85.0 Cr) even as it rose 13.0% QoQ (₹33.1 Cr). Neither this quarter nor the year-ago quarter carried exceptional items, so the YoY decline is entirely operational, not a base-effect from one-offs. No formal street consensus for the quarter could be located in available previews; the commentary going into the print flagged FY27 as the year operating leverage was expected to start converting revenue growth into PAT expansion — this quarter runs counter to that framing on a YoY basis, so vsStreet is marked unknown rather than guessed. Consolidated NPM compressed to 3.2% from 9.7% a year ago (roughly flat versus 3.1% last quarter), and EBITDA margin eased to an estimated ~18.9% from ~22.1% a year ago. The squeeze traces to two lines below EBITDA: finance costs more than doubled YoY to ₹83.4 Cr (from ₹32.6 Cr) and depreciation rose 88.8% to ₹100.8 Cr (from ₹53.4 Cr), both reflecting the debt- and capex-funded capacity build-out. Three newly consolidated subsidiaries under ramp-up contributed combined revenue of ₹40.3 Cr but a net loss of ₹4.6 Cr for the quarter, directly matching management's Q4 guidance that near-term EBITDA margins would be hit by initial losses from new facilities. Tellingly, standalone (parent-only) PAT grew 13.1% YoY to ₹66.5 Cr on revenue of ₹483.6 Cr (+29.5% YoY) — the wide swing between standalone and consolidated growth confirms the drag sits with the newer Group subsidiaries and their financing, not the core hospital business. On guidance, the quarter reads as on-track rather than a miss: management had flagged margin pressure from new-unit ramp-up and a plan to bring net debt/EBITDA to 1:2 (from over ₹3,000 Cr of debt) via a QIP. The company closed that QIP during the quarter, issuing 1.987 Cr shares at ₹755 to raise ₹1,500 Cr, with proceeds still largely parked in mutual funds as of 30 June per the filing notes — which explains why finance costs had not yet eased. Shareholders separately cleared, at a 9 July EGM, up to ₹600 Cr of convertible warrants to promoters for further deleveraging headroom. The Board also approved loans/guarantees of up to ₹650 Cr to group entities and a draft O&M and Call Option agreement with Golden Lan Solutions and Sarwottam Healthcare (execution pending); separately, the Group completed one hospital O&M agreement this quarter, accounted for as a business combination under Ind AS 103. No standalone press-release commentary was available in the filing beyond these operational notes. Going into Q2 FY27, the markers to watch are whether finance costs start declining as QIP proceeds are deployed toward debt paydown, whether the loss-making new subsidiaries (₹4.6 Cr loss on ₹40.3 Cr revenue this quarter) narrow toward the 12-18 month EBITDA-breakeven management guided for new units, and whether consolidated NPM begins recovering off its current 3.2% base.